{
    "nctId": "NCT00769080",
    "briefTitle": "The Performance of Patient Support Program in Early Stage Breast Cancer",
    "officialTitle": "A Prospective, Multicentre, Controlled, Observational Study to Evaluate the Performance of Patient Support Programme (PSP) in Improving Patient Adherence With Adjuvant Aromatase Inhibitors (AI) Medication for Postmenopausal, Early Stage Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 524,
    "primaryOutcomeMeasure": "compare the 1-year adherence",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Provide signed and dated written Informed Consent\n* Have been taking upfront AI adjuvant therapy in line with current SmPC\n* Be capable of completing drug intake by herself\n* Be capable of understanding Chinese\n\nExclusion Criteria:\n\n* Upfront adjuvant hormonal therapy by an AI to which upfront adjuvant indication has not been granted by SFDA\n* Upfront adjuvant AI medication which has exceeded over eight weeks\n* Previous adjuvant hormonal therapy for breast cancer lasting over 8 weeks other than AI\n* Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}